drugset / Trial / NCT07384390
TH-CAR-027 for Grade 4 Gliomas
Phase 0
Not yet recruiting
21 enrolled
Shanghai Tongji Hospital, Tongji University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive grade 4 glioma
Timeline
- Start
- 2026-01-30
- Primary completion
- 2028-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TH-CART-027 | Cell therapy | — | Other |